Cappella Peel Away assets include a license agreement on patents related to the peel-away sheath technology for a stent delivery system, technical specifications and drawings, clinical and regulatory documentation and equipment from Cappella.

Cappella will keep the rights to the peel-away sheath technology for use with its Sideguard coronary bifurcation stent and for other potential applications including peripheral vascular indications.

According to Stentys, the catheter technology will enable the implantation of the Self-Apposing stent in the same manner as a conventional balloon-expandable stent. This technology, which has been used as part of Cappella’s Sideguard stent, is CE Marked in Europe.

This technology will be incorporated into Stentys’ next-generation delivery system for the company’s line of bare metal and drug-eluting stents. The company plans to have the new system in the market in 2015.

Stentys co-founder and CEO Gonzague Issenmann said this is the company’s first strategic acquisition, and it results from its active research efforts, including constant monitoring of the landscape for complementary tools to add to its portfolio.

"We are very excited about the potential for the Cappella Peel Away catheters to offer cardiologists an even friendlier user experience for implantation of our stents and allow more heart attack patients to benefit from Stentys’ Self-Apposing technology," Issenmann added.

The transaction is subject to closing conditions.